Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data

Lennox-Gastaut syndrome (LGS) is one of the most severe forms of childhood-onset epilepsy, accounting for approximately 1% to 4% of all childhood epilepsy cases, with peak onset occurring between the ages of 3 and 5 years [1–3]. Although the etiology of LGS is frequently unknown, the condition is characterized by a triad of symptoms, including impairment of cognitive function, slow spike-and-wave complexes on electroencephalogram (EEG) recordings, and multiple seizure types, making it particularly difficult to control [1,3].

0